Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Rhea-AI Summary

Aclarion (Nasdaq: ACON, ACONW) published a CEO shareholder letter outlining 2026 priorities: expand adoption of the Nociscan platform, pursue reimbursement with U.S. regional insurers, grow clinical evidence, and advance commercial engagement with physicians and imaging centers.

The company highlighted an initial CLARITY trial readout in Q4 2026 and a strong balance sheet with cash runway into 2028 to support execution of these catalysts.

Positive

• Initial CLARITY readout scheduled for Q4 2026
• Cash runway available into 2028
• Expanding commercial engagement with physicians and imaging centers
• Advancing reimbursement initiatives in the UK and US

Negative

• Broader payer adoption depends on securing reimbursement from regional US insurers
• Clinical and commercial progress hinges on the pending CLARITY readout in Q4 2026

Key Figures

CLARITY trial readout: Q4 2026 Cash runway: into 2028

2 metrics

CLARITY trial readout Q4 2026 Initial CLARITY clinical trial readout timing from CEO shareholder letter

Cash runway into 2028 Management statement of strong balance sheet supporting operations

Market Reality Check

Price: $3.32 Vol: Volume 114,041 is 1.52x t...

high vol

$3.32 Last Close

Volume Volume 114,041 is 1.52x the 20-day average of 74,868, indicating elevated interest ahead of the CEO letter. high

Technical Trading below the 200-day MA of 6.21 with price at 3.32, remaining well under the longer-term trend and far below the 24.91 52-week high.

Peers on Argus

ACON was up 2.47% pre-news with mixed peers: WORX up 5.34%, while BFRG, VSEE, an...

1 Up 1 Down

ACON was up 2.47% pre-news with mixed peers: WORX up 5.34%, while BFRG, VSEE, and DRIO were down and POAI was flat, pointing to largely stock-specific dynamics rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	Conference participation	Positive	+0.6%	ROTH Conference meetings on Nociscan adoption and strong balance sheet.
Mar 12	Conference attendance	Positive	-3.2%	CEO attending LSI USA 2026 to meet investors and partners.
Feb 05	Shareholder letter	Positive	-12.6%	2026 priorities, CLARITY trial timelines and cash runway into 2028.
Feb 03	Commercial expansion	Positive	-2.1%	Source Healthcare agreement to expand Nociscan use and real-world data.
Jan 13	Equity financing	Positive	-6.9%	Common-stock financing strengthening cash position and extending runway.

Pattern Detected

Recent news has mostly been positive or strategic, yet the stock often traded down following these updates, with only 1 of 5 events showing a positive price reaction.

Recent Company History

Over recent months, Aclarion has emphasized balance sheet strength, clinical progress, and commercialization of Nociscan. A January financing added cash and extended runway into 2028, followed by a new high-volume practice agreement and a 2026 shareholder letter detailing CLARITY trial timelines and capital structure changes. Conference participation and investor outreach in March 2026 continued this awareness push. Today’s CEO shareholder letter reiterates 2026 catalysts, growing evidence, and reimbursement progress, fitting into a consistent narrative of building clinical and commercial foundations.

Market Pulse Summary

This announcement reiterates Aclarion’s 2026 value-creation priorities, including an initial CLARITY...

Analysis

This announcement reiterates Aclarion’s 2026 value-creation priorities, including an initial CLARITY trial readout in Q4 2026 and a stated cash runway into 2028. It emphasizes growing Nociscan adoption, expanding clinical evidence, and advancing reimbursement efforts in the U.S. and U.K. In the recent past, the company has combined capital raises with commercial and clinical milestones, so investors may watch for concrete payer coverage decisions, CLARITY milestones, and additional real-world data as key validation points.

Key Terms

biomarkers, augmented intelligence (ai), reimbursement coverage, clinical trial, +1 more

5 terms

biomarkers medical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

augmented intelligence (ai) technical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help"

Augmented intelligence is the use of computer tools and software to enhance human decision-making rather than replace it — think of a digital co‑pilot that highlights options, spots patterns, and runs calculations faster than a person alone. For investors, it matters because these tools can boost productivity, improve accuracy, and create new products or services, which can change a company’s revenue, costs, competitive position and exposure to regulatory or ethical risks.

reimbursement coverage financial

"Pursuing reimbursement coverage from one or more regional insurance providers"

Reimbursement coverage is when health insurers or government programs agree to pay for a medical product, treatment, or service and set the rules for who qualifies and how much they will pay. For investors, it’s a key gatekeeper for sales and adoption—like a major retailer choosing to carry an item—because having broad coverage makes it much easier for patients to access a therapy and for a company to earn predictable revenue, while lack of coverage can severely limit market uptake.

clinical trial medical

"The update also highlights the company’s ongoing CLARITY clinical trial, expansion"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

cash runway financial

"Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo."

Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.

AI-generated analysis. Not financial advice.

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption

Initial CLARITY trial readout in Q4 2026

Strong Balance Sheet with Cash Runway into 2028

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company’s recent momentum and value-creating priorities for 2026.

The letter highlights Aclarion’s continued momentum in expanding adoption of its Nociscan platform, growing clinical evidence, and advancing reimbursement initiatives in both the United Kingdom and the United States. The update also highlights the company’s ongoing CLARITY clinical trial, expansion of commercial engagement with physicians and imaging centers, and its strong balance sheet supporting continued execution.

“Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Brent Ness, Chief Executive Officer of Aclarion. “With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.”

The full CEO Shareholder Letter is available on the company’s website.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected later in 2026, followed by the public disclosure of early interim results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

FAQ

When will Aclarion (ACON) report initial CLARITY trial results?

The initial CLARITY trial readout is expected in Q4 2026. According to the company, this readout is a key 2026 catalyst tied to adoption and clinical evidence for Nociscan.

What does Aclarion say about reimbursement efforts for Nociscan in 2026?

Aclarion is pursuing reimbursement coverage from one or more regional US insurers. According to the company, this step aims to support broader payer adoption and commercial access.

How long is Aclarion's cash runway and what does it mean for investors?

Aclarion reports a strong balance sheet with cash runway into 2028. According to the company, this funding horizon supports execution of 2026 commercial and clinical priorities.

How is Aclarion expanding commercial adoption of Nociscan in 2026?

The company is increasing engagement with physicians and imaging centers to expand Nociscan use. According to the company, efforts include growing clinical evidence and payer outreach in the UK and US.

Where can investors read the Aclarion CEO shareholder letter published March 19, 2026?

The full CEO shareholder letter is available on Aclarion's website. According to the company, the letter details 2026 priorities, clinical progress, and reimbursement initiatives.